82 related articles for article (PubMed ID: 24413571)
1. Inducing anti-tumor cytokines and an immune response in melanoma by inhibition of MIA using the peptide AR71.
Riechers A; Schmidt J; Dettmer K; Oefner P; Jachimczak P; Schneider A; Bosserhoff AK
Eur J Dermatol; 2013; 23(6):820-5. PubMed ID: 24413571
[TBL] [Abstract][Full Text] [Related]
2. Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition.
Schmidt J; Riechers A; Stoll R; Amann T; Fink F; Spruss T; Gronwald W; König B; Hellerbrand C; Bosserhoff AK
PLoS One; 2012; 7(5):e37941. PubMed ID: 22666418
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques.
Jachimczak P; Apfel R; Bosserhoff AK; Fabel K; Hau P; Tschertner I; Wise P; Schlingensiepen KH; Schuler-Thurner B; Bogdahn U
Int J Cancer; 2005 Jan; 113(1):88-92. PubMed ID: 15386421
[TBL] [Abstract][Full Text] [Related]
4. MIA--a new target protein for malignant melanoma therapy.
Schmidt J; Riechers A; Bosserhoff AK
Histol Histopathol; 2013 Apr; 28(4):421-6. PubMed ID: 23192727
[TBL] [Abstract][Full Text] [Related]
5. Melanoma inhibitory activity in melanoma diagnostics and therapy - a small protein is looming large.
Riechers A; Bosserhoff AK
Exp Dermatol; 2014 Jan; 23(1):12-4. PubMed ID: 24372647
[TBL] [Abstract][Full Text] [Related]
6. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression.
Wagner SN; Schultewolter T; Wagner C; Briedigkeit L; Becker JC; Kwasnicka HM; Goos M
Lab Invest; 1998 May; 78(5):541-50. PubMed ID: 9605179
[TBL] [Abstract][Full Text] [Related]
7. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
[TBL] [Abstract][Full Text] [Related]
9. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
10. Effect of Thuja occidentalis and its polysaccharide on cell-mediated immune responses and cytokine levels of metastatic tumor-bearing animals.
Sunila ES; Hamsa TP; Kuttan G
Pharm Biol; 2011 Oct; 49(10):1065-73. PubMed ID: 21591821
[TBL] [Abstract][Full Text] [Related]
11. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
12. Functional role of MIA in melanocytes and early development of melanoma.
Poser I; Tatzel J; Kuphal S; Bosserhoff AK
Oncogene; 2004 Aug; 23(36):6115-24. PubMed ID: 15208686
[TBL] [Abstract][Full Text] [Related]
13. Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens.
Perez RP; Zhang P; Bosserhoff AK; Buettner R; Abu-Hadid M
Hum Pathol; 2000 Nov; 31(11):1381-8. PubMed ID: 11112213
[TBL] [Abstract][Full Text] [Related]
14. Influence of various cytokines on the induction of lymphokine-activated killer cells.
Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
[TBL] [Abstract][Full Text] [Related]
15. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
[TBL] [Abstract][Full Text] [Related]
16. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model.
Ma D; Luyten GP; Luider TM; Niederkorn JY
Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):435-41. PubMed ID: 7843912
[TBL] [Abstract][Full Text] [Related]
17. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo.
Guba M; Bosserhoff AK; Steinbauer M; Abels C; Anthuber M; Buettner R; Jauch KW
Br J Cancer; 2000 Nov; 83(9):1216-22. PubMed ID: 11027436
[TBL] [Abstract][Full Text] [Related]
19. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
[TBL] [Abstract][Full Text] [Related]
20. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
